Direct Flow Medical Inc., a transcatheter heart valve innovator focused on improving patient outcomes has received the CE Mark for an enhanced transfemoral delivery system for the Direct Flow Medical Transcatheter Aortic Valve System.
The swift migration to cloud computing and data recovery services shows no signs of slowing, with half of organizations reporting they expect to boost their cloud services budgets over the next 18 months, according to a new study conducted by IDG Research Services on behalf of Sungard Availability Services and EMC Corp.
LoneStar Heart Inc. announced that it received the CE mark (Conformite Europeene) for its Algisyl-LVR hydrogel implant, the company's lead product for the treatment of advanced heart failure (HF).
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Preventice Inc. announced improvements to its BodyGuardian Remote Monitoring System that have the potential to simplify the remote monitoring experience for patients and contribute to a more efficient care delivery process when transitioning between monitoring needs for individual patients.
CardiacAssist Inc. announced that the first Protek Duo veno-venous extracorporeal life support (VV ECLS) kit was utilized Sept. 24, at Memorial Hermann Hospital in Houston.
Stanford Children’s Health is using cutting-edge videogame technology to get parents the information they need about the complex medical procedures their children might face.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
October 8, 2014 — At the recent Transcatheter Cardiovascular Therapeutics (TCT) meeting, representatives from Cardinal Health and physicians from leading healthcare institutions led discussions to help interventionalists explore the balance between innovative approaches to lowering healthcare costs and maintaining high-quality patient care.
October 8, 2014 — New updates to the Society for Cardiovascular Angiography and Interventions (SCAI) appropriate use criteria (AUC) calculator tool will help healthcare providers in making treatment decisions for patients who are candidates for diagnostic catheterization or imaging for heart failure. The updated tool, available online or through an iOS and Android app, is now available for download.
October 8, 2014 — Abbott announced the start of the ABSORB IV clinical trial, which will test whether the Absorb bioresorbable vascular scaffold (BVS) is more cost effective and offers a higher quality of life than a best-in-class, permanent, metallic drug-eluting stent.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Clinical trial results by Recover Right revealed a survival rate of 73 percent in the total patient population. Recover Right was an FDA-approved, prospective, multicenter, single arm study designed to evaluate the safety and probable benefit of the Impella RP in patients with right ventricular failure (RVF) refractory to medical treatment and deemed to require hemodynamic support.
St. Jude Medical Inc. announced 12-month outcome data from the EnligHTN III study, which demonstrated a continuation of safe, rapid and effective treatment with the next-generation EnligHTN Renal Denervation System for patients with drug-resistant, uncontrolled hypertension.
More than 40 percent of Americans aged 40 and older have experienced one or more of the most common symptoms[1] of peripheral arterial disease (PAD).
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
October 8, 2014 — Miracor Medical Systems announced that results from the prospective multicenter safety and feasibility study, ‘Prepare RAMSES,’ were presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference last month in Washington, D.C., by co-investigator Tim P. van de Hoef, M.D., fellow of Jan Piek, M.D., Ph.D., principal investigator for the trial at Academic Medical Center, University of Amsterdam.
Claret Medical announced the first patient has been successfully treated in its SENTINEL trial, a multicenter pivotal trial of the Sentinel cerebral protection system (CPS). The landmark trial is the first prospective, randomized, controlled, blinded trial in the United States to evaluate the role of cerebral protection during transcatheter aortic valve replacement (TAVR).
Amaranth Medical announced patient enrollment in multiple centers in Colombia, South America in MEND-II, a clinical trial to assess safety and feasibility of the company's Fortitude Sirolimus-Eluting Bioresorbable Scaffold in patients with symptomatic coronary artery disease.